Roche Beats Q3 Sales Estimates but Shares Slip
Roche posted third-quarter sales of 16.13 billion Swiss francs, beating estimates on steady demand for Ocrevus. However, shares slipped after cheaper copycats impacted Xolair sales.
Xurve View
Insights:
Xurve View
ROCHE HOLDING AG-BR posted a 7% rise in third-quarter revenue to 16.13 billion Swiss francs ($19.61 billion) on Thursday, beating analyst expectations. The beat was driven by strong demand for core medicines like Ocrevus, helping offset upcoming patent expiries. Shares fell 1.1% in morning trade after cheaper copycats impacted key drug sales.
